{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.9","spread":"21.9","upperLimit":"112.4","value":"54.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"261"}],"units":"Participants"}],"description":"Persistent infection is when a participant is positive by PCR for the same HPV type in external genital swabs or tissue specimens collected at consecutive visits at least 6 months (+/-1 month visit window) apart. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was from beginning of long-term follow-up or when a study participant reached 16 years of age, whichever came later.","dispersionType":"95% Confidence Interval","groups":[{"description":"In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension studies, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1) and for immunogenicity, effectiveness, and safety up to Month 126 (EXT2).","id":"OG000","title":"Extension Study: 9- to 15-Year-Old Males"}],"paramType":"NUMBER","populationDescription":"The per-protocol effectiveness population, which included participants who were seronegative (by cLIA) to the relevant HPV type(s) at Day 1 (seronegative to both HPV 6 and 11 for analysis of HPV 6 and 11-related endpoints), received all 3 doses of 9vHPV vaccine with the correct dose of the clinical material within 1 year, and had no other protocol violation that could interfere with evaluation of vaccine effectiveness.","reportingStatus":"POSTED","timeFrame":"Up to ~Month 126","title":"Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Males","type":"SECONDARY","unitOfMeasure":"Cases per 10,000 person-years"}